Oppenheimer analyst Michelle Gilson does not view Santhera's announcement that the FDA did not support its plans to file a New Drug Application for its Raxone for the treatment of Duchenne muscular dystrophy, or DMD, as a negative read-through for Sarepta. The analyst recommends buying Sarepta's shares on weakness, ahead of the upcoming FDA decision on its eteplirsen for the treatment of DMD. Gilson believes there are key differences between Santhera's and Sarepta's data sets, with eteplirsen's data showing it can support accelerated approval based on dystrophin as a biomarker. Oppenheimer has an Outperform rating and a $60 price target Sarepta's shares.